Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports.

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Zymeworks (NasdaqGS:ZYME) with a Outperform ...

Zymeworks Inc (ZYME) navigates a challenging year with strategic pivots and robust partnership earnings, despite increased ...

Capital, LLC EcoR1, a director at $ZYME, bought 468,356 shares of the company on 03-13-2025 for an estimated $5,847,237. This trade was reported by Quiver ...

VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology ...